Tirzepatide for the Concurrent Treatment of Obesity and Type 1 Diabetes

Obesity Clinical Trial

— TZP-T1D  

Official title:

Tirzepatide for the Concurrent Treatment of Obesity and Type 1 Diabetes

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06180616
• Other study ID #: TZP-T1D
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 2024
• Est. completion date: July 2025

Study information

• Verified date: January 2024
• Source: Royal North Shore Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a 2-arm, double blinded, randomised clinical trial where 72 participants will be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide treatment for 32 weeks. The primary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks adjunctive to insulin treatment can reduce body weight in patients with T1D and obesity when compared to insulin treatment alone. The secondary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks can improve glycaemic control (measured by hbA1c), improve time in range, reduce insulin requirements, and reduce the severity of comorbidities in people with obesity and T1D.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 72
• Est. completion date: July 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age 18-70 years at screening
• A clinical diagnosis of T1DM for at < 12 months at time of screening
• Body mass index = 30kg/m2
• HbA1c = 10%
• Capable and willing to self-inject tirzepatide once per week
• In women of childbearing potential, a negative pregnancy test and willing to use effective contraception consistently for the duration of the study which is defined

as:

• an intrauterine device,
• oral contraceptive pill, or
• combination of two barrier methods with one being male condom
• Able and willing to provide written informed consent for study participation
• Able and willing to use Easy Diet Diary
• Able and willing to keep an exercise log
• Patient on hybrid closed loop system for >3 months
• Willing to share devices data uploads
• Has current glucagon product to treat severe hypo
• Has current ketone meters to check ketones

Exclusion Criteria:

• Age < 18 years and > 70 years
• A clinical diagnosis of diabetes type other than T1DM
• HbA1c < 10%
• Use of GLP-1 receptor agonist within 1 month of study screening
• Use of any glucose lowering medications aside from insulin within 1 month of study screening
• Obesity that is induced by other endocrine disorders
• Pregnancy or positive pregnancy test at time of screening, or unwilling to use effective contraception consistently for the duration of the study which is defined

as:

• an intrauterine device,
• oral contraceptive pill, or
• combination of two barrier methods with one being male condom
• Active proliferative diabetic retinopathy, maculopathy or severe NPDR requiring acute treatment
• Known gastric emptying abnormality
• History of chronic or acute pancreatitis, uncontrolled hypertension, acute cardiovascular condition within 3 months
• Less than 12 months of insulin treatment
• Not willing to use a NovoPen 6 to record insulin dosing if currently using multiple daily injections
• Non compatible devices (e.g. pump, CGM or smart phones) for data transfer
• Not willing to share device data
• Current use of any steroidal medication, or anticipated long-term steroidal treatment during the study period
• Serum triglycerides >500 mg/dL
• Planning for bariatric surgery during the study period
• eGFR <45 ml/min/1.73 m^2
• History of severe hypoglycaemia (within 3 months of trial period)
• History of diabetic ketoacidosis (within 3 months of trial period)
• History of stroke (within 3 months of trial period)
• History of congestive heart failure class III or IV
• History of acute or chronic liver disease
• History of allergy to any form of insulin, GLP-1RA or its excipients
• History of malignancy requiring chemotherapy, surgery or radiation (within 5 years of trial period)
• Have a pacemaker, or metal implants
• Participation to other intervention trials during the study period
• Presence of any comorbidities or medical conditions, such as severe psychiatric disorders, that render a person unfit for the study at the discretion of the investigators.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Obesity
• Type 1 Diabetes Mellitus

Intervention

Drug:
• Tirzepatide
Tirzepatide will be self-administered subcutaneously by study participants via an injection. The drug will be taken weekly following the schedule: 4 weeks at 2.5 mg QW, 4 weeks at 5.0 mg QW, 4 weeks at 7.5 mg QW, 4 weeks at 10.0 mg QW, 4 weeks at 12.5 mg QW, 12 weeks at 15 mg QW. If gastrointestinal adverse effects occur during dose escalation, the dose can be held at the lowest tolerable dose for a longer period (up to 3 weeks) until an increment can be tolerated (analysis will be by intention to treat).

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Royal North Shore Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Body weight	Percent body weight change	32 weeks
Secondary	hbA1c	Change in hbA1c levels	32 weeks
Secondary	Time in range	Change in continuous glucose monitoring (CGM) metrics (time in range (3.9-10mmol/L))	32 weeks
Secondary	Total daily insulin dose	Change in insulin dose (total daily dose, units/kg of body weight)	32 weeks
Secondary	Insulin carbohydrate ratio	Change in insulin dose (insulin carbohydrate ratio (units per g))	32 weeks
Secondary	Waist and neck circumference	Change in waist and neck circumference	32 weeks
Secondary	Blood pressure	Change in blood pressure	32 weeks
Secondary	Mean glucose	Change in continuous glucose monitoring (CGM) metrics (mean glucose)	32 weeks
Secondary	Time in hypoglycaemia	Change in continuous glucose monitoring (CGM) metrics (time in hypoglycaemia (mild < 3.9, severe < 2.5mmol/L))	32 weeks
Secondary	Time in hyperglycaemia	Change in continuous glucose monitoring (CGM) metrics (time in hyperglycaemia (mild >10, severe 13.9mmol/L))	32 weeks
Secondary	Continuous glucose monitoring	Change in continuous glucose monitoring (CGM) metrics (SD)	32 weeks
Secondary	Continuous glucose monitoring	Change in continuous glucose monitoring (CGM) metrics (CV)	32 weeks
Secondary	Continuous glucose monitoring	Change in continuous glucose monitoring (CGM) metrics (CONGA)	32 weeks
Secondary	Continuous glucose monitoring	Change in continuous glucose monitoring (CGM) metrics (J-index)	32 weeks
Secondary	Continuous glucose monitoring	Change in continuous glucose monitoring (CGM) metrics (MAGE)	32 weeks
Secondary	Total cholesterol	Change in lipid parameters (total cholesterol)	32 weeks
Secondary	Triglyceride	Change in lipid parameters (triglyceride)	32 weeks
Secondary	LDL-C	Change in lipid parameters (LDL-C)	32 weeks
Secondary	HDL-C	Change in lipid parameters (HDL-C)	32 weeks
Secondary	ACR	Change in albumin to creatinine ratio (ACR)	32 weeks
Secondary	eGFR	Change in renal function (eGFR)	32 weeks
Secondary	HSI	Change in NAFLD biomarker HSI. Hepatic steatosis defined as HSI > 36	32 weeks
Secondary	FIB-4	Change in NAFLD biomarker FIB-4. Hepatic steatosis defined as FIB-4 index = 1.3 or < 1.3	32 weeks